培非格司亭维持子宫内膜癌患者的相对剂量强度并减少住院治疗。
Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer.
机构信息
Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan
Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan.
出版信息
In Vivo. 2020 Nov-Dec;34(6):3669-3673. doi: 10.21873/invivo.12214.
BACKGROUND/AIM: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy.
PATIENTS AND METHODS
We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity ≥85%.
RESULTS
In the pegfilgrastim vs. the control group, body mass index (26.6±5.9 vs. 23.4±4.4), rate of relative dose intensity ≥85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0±2.1 vs. 18±5.6 days), unscheduled hospital visits (1.1±1.8 vs. 5.8±5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58±1.7 vs. 6.4±5.1 days) were significantly lower.
CONCLUSION
Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency.
背景/目的：关于在妇科肿瘤学中使用培非格司亭的数据有限。我们评估了其在维持化疗期间剂量强度的疗效。
患者和方法
我们回顾性地检查了 65 名女性（26 名培非格司亭使用者）的数据，这些女性接受了原发性手术治疗，用于 I B-IV 期子宫内膜癌，并接受了含铂和紫杉烷的辅助化疗；主要结果是相对剂量强度≥85%。
结果
在培非格司亭组与对照组相比，体重指数（26.6±5.9 vs. 23.4±4.4）、相对剂量强度≥85%的发生率（88.5% vs. 15.4%）和其他不良事件发生率显著更高；中性粒细胞减少症发生率、化疗期间总住院天数（11.0±2.1 vs. 18±5.6 天）、非计划住院天数（1.1±1.8 vs. 5.8±5.1 天）和非计划粒细胞集落刺激因子注射天数（0.58±1.7 vs. 6.4±5.1 天）显著降低。
结论
培非格司亭可维持妇科癌症化疗期间的剂量强度≥85%，并降低住院频率。
Zotero 插件